Лечение мигрени завтра и послезавтра. Влияние на путь CGRP


DOI: https://dx.doi.org/10.18565/pharmateca.2019.13.58-62

К.В. Скоробогатых, Ю.Э. Азимова

Университетская клиника головной боли, Москва, Россия
Мигрень – это хроническое неврологическое заболевание, характеризующееся высокой распространенностью и значительным снижением качества жизни. Сочетание этих факторов приводит к существенному негативному социоэкономическому влиянию. В последнее время происходит заметный прогресс в понимании патогенеза мигрени, что приводит к появлению новых классов препаратов для лечения этого заболевания. В обзоре рассмотрены история изучения кальцитонин-ген родственного пептида (CGRP) в патогенезе мигрени и характеристики новых препаратов, воздействующих на путь CGRP-антагонистов CGRP-рецепторов («джепантов») и моноклональных антител к рецептору CGRP/CGRP.
Ключевые слова: мигрень, CGRP, кальцитонин-ген родственный пептид, джепанты, моноклональные антитела

Литература


1. Steiner T.J., et al. Migraine: the seventh disabler. J Headache Pain. 2013;14:1. Doi: 10.1186/1129-2377-14-1.


2. Ayzenberg I., Katsarava Z., Sborowski A., et al.; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012;32(5):373–81. Doi: 10.1177/0333102412438977.


3. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. Neurol. 2018;17(11):954–76. Doi: 10.1016/S1474- 4422(18)30322-3.


4. Linde M., Gustavsson A., Stovner L.J., et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2011;19(5):703–11. Doi: 10.1111/j.1468-1331.2011.03612.x.


5. Ayzenberg I., Katsarava Z., Sborowski A., et al. Headache-attributed burden and its impact on productivity and quality of life in Russia: structured healthcare for headache is urgently needed. Eur J Neurol. 2014;21(5):758–65. Doi: 10.1111/ene.12380.


6. Evers S., Afra J., Frese A., et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81. Doi: 10.1111/j.1468-1331.2009.02748.x.


7. Marmura M.J., Silberstein S.D., Schwedt T.J. The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies. Headache. J Head Face Pain. 2015;55(1):3–20. Doi: 10.1111/head.12499.


8. Silberstein S.D. Preventive Migraine Treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973–89. Doi: 10.1212/CON.0000000000000199.


9. Goadsby P.J., Holland P.R., Martins-Oliveira M., et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553–622. Doi: 10.1152/physrev.00034.2015.


10. Ray B., Wolff H. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg. 1940;41:813–56.


11. Moskowitz M.A., Reinhard J.F. Jr., Romero J., et al. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet. 1979;2(8148):883–85. Doi: 10.1016/s0140-6736(79)92692-8


12. Uddman R., Edvinsson L., Ekman R., et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P. Neurosci Letters. 1985;62(1):131–36. Doi: 10.1016/0304-3940(85)90296-4. Doi: 10.1016/0304-3940(85)90296-4.


13. Скоробогатых К.В., Табеева Г.Р. Кальцитонин-ген-родственный пептид в патогенезе первичных головных болей. Российский журнал боли. 2010;(1):1–52.


14. Goadsby P.J., Edvinsson L., Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988);23(2):193–96. Doi:10.1002/ana.410230214.


15. Zagami A.S., Goadsby P.J., Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropept. 1990;16(2):69–75. Doi: 10.1016/0143-4179(90)90114-e.


16. Goadsby P.J., Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–87. Doi: 10.1002/ana.410280213.


17. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993);33(1):48–56. Doi: 10.1002/ana.410330109.


18. Lassen L., Haderslev P., Jacobsen V., et al. CGRP May Play A Causative Role in Migraine. Cephalalgia. 2002;22(1):54–61. Doi: 10.1046/j.1468-2982.2002.00310.x.


19. Warfvinge K., Edvinsson L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia. 2017. 033310241772887. Doi: 10.1177/0333102417728873.


20. Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache. J Head Face Pain. 2017;57:47–55. Doi:10.1111/head.13081.


21. Olesen J., Diener H.-C., Husstedt I. W., et al. Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. N Engl J Med. 2004;350(11):1104–10. Doi: 10.1056/nejmoa030505.


22. Edvinsson L., Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet. 2010;376(9741):645–55. Doi: 10.1016/s0140-6736(10)60323-6.


23. Ho T.W., Connor K.M., Zhang Y., et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurol. 2014;83:958–66. Doi: 10.1212/WNL.0000000000000771.


24. Marcus R., Goadsby P.J, Dodick D.W., et al. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114–25. Doi: 10.1177/0333102413500727.


25. Voss T., Lipton R.B., Dodick D.W., et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–98. Doi: 10.1177/0333102416653233.


26. Lipton R.B., Croop R., Stock E.G., et al. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142–49. Doi: 10.1056/nejmoa1811090.


27. URL: https://clinicaltrials.gov/ct2/show/NCT02848326


28. Bigal M.E., Walter S., Rapoport A.M. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886–95. Doi: 10.1111/bcp.12591.


29. Silberstein S., Lenz R., Xu C. Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know. Headache. J Head Face Pain. 2015;55(8):1171–82. Doi: 10.1111/head.12642.


30. Tepper S.J. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. J Head Face Pain. 2018;58( Suppl. 3):238–75. Doi: 10.1111/head.13379.


31. Sun H., Dodick D.W., Silberstein S., et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet. Neurol. 2016;15:382–90. Doi: 10.1016/S1474-4422(16)00019-3.


32. Dodick D.W., Ashina M., Brandes J.L., et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37. Doi: 10.1177/0333102418759786.


33. Goadsby P.J., Reuter U., Hallström Y., et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123–22. Doi: 10.1056/NEJMoa1705848.


34. Tepper S.J., Ashina M., Reuter U., et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. Neurol. 2017;16:425–34. Doi: 10.1016/S1474-4422(17)30083-2.


35. Bigal M.E., Dodick D.W., Rapoport A.M., et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet. Neurol. 2015;14:1081–90. Doi: 10.1016/S1474-4422(15)00249-5.


36. Dodick D.W., Silberstein S.D., Bigal M.E., et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999–2008. Doi: 10.1001/jama.2018.4853.


37. Bigal M.E., Edvinsson L., Rapoport A.M., et al. Silberstein SD (2015a) safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet. Neurol. 2015;14:1091–100.


38. Silberstein S.D., Dodick D.W., Bigal M.E., et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–22. Doi: https://doi.org/10.1056/nejmoa1709038.


39. Dodick D.W., Goadsby P.J., Spierings E.L., et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin generelated peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–92. Doi: 10.1016/S1474-4422(14)70128-0.


40. Skljarevski V., Oakes T.M., Zhang Q., et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA. Neurol. 2018;75:187–93. Doi: 10.1001/jamaneurol.2017.3859.


41. Stauffer V.L., Dodick D.W., Zhang Q., et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA. Neurol. 2018;75:1080–88. Doi: 10.1001/jamaneurol.2018.1212.


42. Detke H.C., Goadsby P.J., Wang S., et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebocontrolled REGAIN study. Neurol. 2018;91:1–11. Doi: https://doi.org/10.1212/ WNL.0000000000006640


43. Dodick D.W., Goadsby P.J., Silberstein S.D., et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet. Neurol. 2014;13:1100–107.


44. A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (PROMISE 1) https://clinicaltrials.gov/ct2/show/NCT02559895 Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2) https://clinicaltrials.gov/ct2/show/NCT02974153 Eptinezumab Alder Biopharmaceuticals https://www.alderbio.com


45. Do T.P., Guo S., Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1). Doi: 10.1186/s10194-019-0974-3.


46. Ashina M., Goadsby P.J., Reuter U., et al. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;033310241985408. Doi: 10.1177/0333102419854082.


47. Ning X., Cohen J., Bennett N., et al. Long-Term Safety of Fremanezumab: Results of a 1-Year Study. Neurol. 2019;92(Suppl. 15).


48. Schwedt T., Reuter U., Tepper S.J., et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19(1):92. Doi: 10.1186/s10194-018-0923-6.


49. Bigal M.E., Dodick D.W., Krymchantowski A.V., et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87:41–8. Doi: 10.1212/WNL.0000000000002801.


50. Kudrow D.B. Bigal, Eptinezumab Achieved Meaningful Reductions in Migraine Activity As Early As Day 1 and Were Sustained Through Week 12: Results From PROMISE-2 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Phase 3 Trial in Chronic Migraine. Neurology. 2016;87.


51. Kudrow D., Lipton R., Silberstein S., et al. Eptinezumab for Prevention of Chronic Migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy–2) Trial. Neurol. 2019;92(Suppl. 15).


52. Sacco S., Bendtsen L., Ashina M., et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1). Doi:10.1186/s10194-018-0955-y.


53. Haanes K.A., Edvinsson L. Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets. CNS Drugs. 2019. Doi:10.1007/s40263-019-00630-6.


Об авторах / Для корреспонденции


Автор для связи: К.В. Скоробогатых, Университетская клиника головной боли, Москва, Россия; e-mail: post.kirill@gmail.com
Адрес: 121467, Россия, Москва, ул. Молодогвардейская, 2, корп. 1


Бионика Медиа